Stock analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
vTv Therapeutics Stock Performance
NASDAQ VTVT opened at $0.37 on Friday. vTv Therapeutics has a one year low of $0.35 and a one year high of $1.05. The company has a market capitalization of $38.82 million, a price-to-earnings ratio of -1.37 and a beta of -0.01. The company’s 50-day simple moving average is $0.43 and its two-hundred day simple moving average is $0.63.
Institutional Trading of vTv Therapeutics
Institutional investors have recently modified their holdings of the company. Pathstone Family Office LLC acquired a new stake in vTv Therapeutics in the 3rd quarter worth approximately $116,000. State Street Corp increased its holdings in shares of vTv Therapeutics by 268.7% during the 2nd quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 150,228 shares in the last quarter. Millennium Management LLC increased its holdings in shares of vTv Therapeutics by 12.0% during the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 14,845 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new stake in vTv Therapeutics in the 2nd quarter worth $30,000. 3.36% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.
- Five stocks we like better than vTv Therapeutics
- How to Read Stock Charts for Beginners
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Want to Profit on the Downtrend? Downtrends, Explained.
- MarketBeat Week in Review – 11/13 – 11/17
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.